Eris Lifesciences logo

Eris Lifesciences financials: balance sheet, profit and loss, cash flow

NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap

Eris Lifesciences Limited · Face value ₹1 · Listed Jun 2017 · Issue price ₹603
Last close ₹1,163.60down ₹11.80 (1.00%)BSE ₹1,163.70

Share price at the NSE close on 29 Oct 2026. Previous close ₹1,175.40.

29 Oct: open ₹1,170.20, high ₹1,183.50, low ₹1,155.50

52-week range of traded prices to 29 Oct 2026
₹1,069.00Low, 26 Oct 2026₹1,740.00High, 9 Dec 2025
Market cap
₹16,144 Cr353rd largest listed
P/E
22.81
P/B
3.90
Dividend yield
0.62%
ROE
19.6%
ROCE
13.4%
Debt to equity
0.58
Volume, NSE
29,73845.0% delivered

Eris Lifesciences' financial statements for the 9 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

9 years at a glance

₹ crore, years to March.Eris Lifesciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
856295Mar 189822910.3Mar 191,0742970Mar 201,2123550.0Mar 211,34740645Mar 221,685374830Mar 232,0093972,735Mar 242,8943752,478Mar 253,1296482,310Mar 26
Peak revenue ₹3,129 Cr, year to Mar 2026; lowest ₹856 Cr, year to Mar 2018

Operating and net margin, per cent

  • Operating margin
  • Net margin
37.6%12.9%37.6%35.1%34.3%35.5%36.0%31.9%33.6%35.2%35.8%34.5%29.6%27.6%29.3%30.1%22.2%19.8%12.9%20.7%Mar 18Mar 20Mar 22Mar 24Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.4% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue3,129
  2. Materials and goods−796
  3. Employee costs−557
  4. Other expenses−657
  5. Operating profit1,120
  6. Depreciation−280
  7. Other income+7.8
  8. One-off items−17
  9. Finance costs−193
  10. Profit before tax638
  11. Tax+9.0
  12. Joint ventures+0.1
  13. Net profit648

What the company owns

  • Plant, investments and other assets₹6,181 Cr
  • Receivables₹680 Cr
  • Inventory₹437 Cr
  • Cash and bank₹67 Cr

What pays for it: net worth and liabilities

  • Net worth₹3,896 Cr
  • Borrowings₹2,310 Cr
  • Other liabilities₹831 Cr
  • Owed to suppliers₹330 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Eris Lifesciences quarterly results

₹ croreMar 2018Mar 2019Mar 2020Mar 2021Filed 14 MayMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 MaySep 2026Twelve monthsFiled 26 Oct
Revenue from operations8569821,0741,2121,3471,6852,0092,8943,1293,330
5346377067818621,1481,3341,8762,0092,169
Materials and goods bought134154172238259352380714796874
Employee costs157191206229252346404505557578
Other expenses242293328314351450550657657718
Operating profit before depreciation3223453684314855376751,0171,1201,161
Operating margin37.6%35.1%34.3%35.5%36.0%31.9%33.6%35.2%35.8%34.9%
Materials, % of revenue15.7%15.6%16.0%19.7%19.2%20.9%18.9%24.7%25.4%26.2%
Employee costs, % of revenue18.4%19.4%19.2%18.9%18.7%20.5%20.1%17.5%17.8%17.3%
Other expenses, % of revenue28.3%29.8%30.6%25.9%26.1%26.7%27.4%22.7%21.0%21.6%
Depreciation and amortisation2636504365117183315280285
Operating profit after depreciation296309318388420420492702841875
Other income26321592611241888
Finance costs11232242685231193188
Profit before one-off items and tax312317331394442405431489656696
One-off items00000000−17−53
Profit before tax312317331394442405431489638643
17263539363034114−9−78
Share of profit of joint ventures and associates–––––––00−2
295291297355406374397375648718
Other comprehensive income–0−1−1−10−3−3−1−1
Total comprehensive income–291295354405374394371646717
Net margin34.5%29.6%27.6%29.3%30.1%22.2%19.8%12.9%20.7%21.6%
Net margin without joint ventures and associates–––––––12.9%20.7%–

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2019Mar 2020Mar 2021Filed 14 MayMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 MaySep 2026Half yearFiled 26 Oct
1,1691,2961,5761,9082,2213,2223,2723,8964,142
1,1511,2961,5761,9082,1962,5862,8543,9034,144
Share capital141414141414141414
Reserves1,1371,2831,5631,8952,1822,5732,8413,8894,130
Belonging to outside owners of subsidiaries1800025636417−7−3
000458302,7352,4782,3102,382
3061651672004432,5321,3812,0772,681
7991911641,0031,2952,3801,393758
Total assets1,5541,5521,8352,2723,6677,0497,0337,3667,581
9721,0731,3681,6452,9034,7475,7715,8265,780
5824804676277652,3021,2631,5401,801
Net debt−322−142−89−1077421,3352,2502,2422,128
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2021Filed 14 MayMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 MaySep 2026Half year
3753782924861,065538637
4444623695871,163662678
5−30−176−99126−458112
Receivables16−20−117−57−9−21057
Inventories−25−235−17−94−101−38
Payables315−109168−6126
Other working capital12−1−53−116162−141−34
Tax paid−69−83−77−101−98−124−41
Capital spending26121841129155297220
Free cash flow350257−550357910241417
−323−320−975−1,828−80−369−285
−82−456881,380−881−314−169
Dividends paid758210001000100
Shares bought back0000000
Shares issued00000011
Net change in cash−3014538104−145183
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Eris Lifesciences dividend history

₹ per shareMar 2018Mar 2019Mar 2020Mar 2021Filed 14 MayMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 May
Earnings per share₹21.39₹21.15₹21.61₹26.16₹29.89₹28.10₹28.82₹25.85₹45.33
Diluted earnings per share₹21.39₹21.13₹21.59₹26.14₹29.88₹28.07₹28.79₹25.81₹45.26
Dividend per share––₹2.87₹5.50₹6.01₹7.35–₹7.35₹7.21
Book value per share–₹83.66₹95.47₹116.10₹140.39₹161.48₹190.11₹209.57₹281.78
Dividend payout––13.1%21.0%20.1%26.2%–28.5%16.1%
Shareholder yield–––0.9%0.9%1.3%0.0%0.5%0.0%
Market cap at the year end (₹ crore)10,9978,8695,0738,2159,3627,78011,47219,29417,670

Ratios

Consolidated, years to March.Eris Lifesciences PE ratio and valuation

RatioMar 2018Mar 2019Mar 2020Mar 2021Filed 14 MayMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 May
Revenue growth–14.8%9.4%12.8%11.2%25.1%19.2%44.0%8.1%
Operating profit growth–7.1%6.8%16.9%12.6%10.7%25.7%50.7%10.1%
Net profit growth–−1.3%1.8%19.8%14.3%−7.8%6.1%−5.6%72.8%
Earnings per share growth–−1.1%2.2%21.1%14.3%−6.0%2.6%−10.3%75.4%
–25.3%24.2%24.7%23.3%18.6%16.4%12.9%18.3%
––−1.0 pts0.5 pts−1.4 pts−4.7 pts−2.2 pts−3.5 pts5.4 pts
From the net margin––−1.7 pts1.5 pts0.7 pts−5.8 pts−2.6 pts−6.2 pts8.1 pts
From asset turnover––2.2 pts0.9 pts−2.1 pts−2.4 pts−5.4 pts1.0 pts1.2 pts
From borrowing––−1.5 pts−1.9 pts0.0 pts3.5 pts5.8 pts1.7 pts−3.9 pts
Return on capital employed–26.4%24.5%24.6%21.5%13.8%8.3%12.2%13.5%
Cash conversion–––105.7%93.2%78.0%122.4%284.3%83.1%
Interest cover28.113.5147.1215.1101.416.05.83.04.4
Debt to equity–0.000.000.000.020.370.850.760.59
Receivable days–3153424463775879
Inventory days–196148145166136182171200
Payable days–200213157166129258170151
Cash conversion cycle, days–28−12304470059129
Working capital days–−1759647591824487
Asset turnover–0.630.690.720.660.570.380.410.43
Assets per rupee of net worth–1.351.271.181.181.452.242.592.13
Sales per rupee of plant–17.7512.3115.568.034.733.984.374.42
Capital spending to depreciation–––0.601.877.190.710.491.06
Plant being built, % of plant in use–1.4%0.0%0.0%14.3%6.0%3.8%10.1%24.2%
No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
8.6%
Cash from operations against operating profit
48.0%
Measure10 years5 years3 years
Revenue growth, yearly rate–20.9%22.9%
Profit growth, yearly rate–11.8%17.5%
Return on equity, average–17.9%15.9%
Return on capital employed, average–13.9%11.3%
Operating margin, average35.0%34.5%34.8%
Net margin, average25.2%21.1%17.8%
Asset turnover, average–0.490.41
Cash conversion cycle, days, average–6063
Interest cover, average59.426.14.4
Debt to equity, average–0.520.73

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations2,7592,089538
Cash from investing−3,571−2,277−369
Cash from financing828185−314
Capital spending1,543581297
Dividends paid2821000
Shares bought back000
Shares issued for cash000
Borrowings raised4,4433,230170
Borrowings repaid2,6252,275282

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––643545
Altman Z-scorePublished threshold 1.81–16.4214.5421.8418.075.012.804.374.56
Beneish M-scorePublished threshold −1.78–––−2.56−2.40−2.25−2.63−2.55−2.01
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––17.9016.9035.5932.45−8.676.65
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––0.920.981.611.47
Receivables growth less revenue growthOur threshold 0 percentage points––77.46−23.283.4256.7424.95−35.3540.19
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––−27.55−2.9316.32−24.8335.96−10.7419.03
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––1.832.462.494.421.83−1.712.15
Assets under construction, years of additionsOur threshold 2 years of additions––0.000.000.160.070.060.140.53
Effective tax ratePublished threshold 17.16 per cent5.538.2610.529.988.237.537.9323.36−1.40
Tax charged less tax paid, % of profitOur threshold 10 percentage points––––−10.60−11.55−15.443.34−20.89
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
8 May 2026India Ratings and Research Private LimitedBank loan facilitiesIND AA; IND A1+Review, Re-affirmStable1,198
8 May 2026India Ratings and Research Private LimitedNon-convertible debenturesIND AAReview, Re-affirmStable625
8 May 2026India Ratings and Research Private LimitedIssuer RatingIND AAReview, Re-affirmStable
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.